Automate Your Wheel Strategy on FULC
With Tiblio's Option Bot, you can configure your own wheel strategy including FULC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FULC
- Rev/Share 1.2804
- Book/Share 3.657
- PB 1.88
- Debt/Equity 0.0355
- CurrentRatio 28.7106
- ROIC -0.0526
- MktCap 371107688.0
- FreeCF/Share 0.121
- PFCF 49.0948
- PE -842.2414
- Debt/Assets 0.0334
- DivYield 0
- ROE -0.002
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 2
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | FULC | Leerink Partners | Market Perform | Outperform | -- | $12 | May 23, 2025 |
| Upgrade | FULC | Cantor Fitzgerald | Neutral | Overweight | -- | $10 | May 15, 2025 |
| Downgrade | FULC | H.C. Wainwright | Buy | Neutral | $17 | $4 | Sept. 13, 2024 |
| Downgrade | FULC | Leerink Partners | Outperform | Market Perform | -- | $4 | Sept. 12, 2024 |
| Downgrade | FULC | RBC Capital Mkts | Outperform | Sector Perform | $15 | $4 | Sept. 12, 2024 |
| Downgrade | FULC | Stifel | Buy | Hold | -- | -- | Sept. 12, 2024 |
| Downgrade | FULC | BofA Securities | Neutral | Underperform | $10 | $2 | Sept. 12, 2024 |
| Downgrade | FULC | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 12, 2024 |
| Upgrade | FULC | BofA Securities | Underperform | Neutral | $5 | $10 | Sept. 9, 2024 |
News
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
FULC
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
FULC
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―
Read More
About Fulcrum Therapeutics, Inc. (FULC)
- IPO Date 2019-07-18
- Website https://www.fulcrumtx.com
- Industry Biotechnology
- CEO Mr. Alexander C. Sapir
- Employees 45
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.